Shattuck Labs Inc (STTK)

Shattuck Labs Inc (STTK) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $548M; returns 1 day -2.0%, 1 week +1.3%, 1 year +196.8%.

Shattuck Labs Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory and immune-mediated diseases. Their primary focus is on SL-325, a DR3 blocking monoclonal antibody, and SL-425, a half-life extended version of SL-325.

Groups STTK belongs to

• Biotechnology
• Clinical Stage Biotech
• Healthcare
• Clinical Stage
• Life Sciences
• Autoimmune Diseases
• Monoclonal Antibodies
• Chronic Inflammatory Diseases
• Bispecific Antibodies

STTK financial model: income statement, cash flow and balance sheet